| 2021 | "3G" Trial: An RNA Editing Signature to Guide Gastric Cancer Chemotherapy | CANCER RESEARCH |
| 2003 | A Case of Paraneoplastic Nephrotic Syndrome in a Patient with Ovarian Carcinoma
| YONSEI MEDICAL JOURNAL |
| 1997 | A Comparative Study of Intravenous Granisetron Versus Intravenous and Oral Ondansetron in the Prevention of Nausea and Vomiting Associated with Moderately Emetogenic Chemotherapy | American Journal of Clinical Oncology |
| 2007 | A comparative study of volumetric analysis, histopathologic downstaging, and tumor regression grade in evaluating tumor response in locally advanced rectal cancer following preoperative chemoradiation | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS |
| 2012 | A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets.
| GUT |
| 2011 | A densely interconnected genome-wide network of microRNAs and oncogenic pathways revealed using gene expression signatures
| PLOS GENETICS |
| 2017 | A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors | CLINICAL CANCER RESEARCH |
| 2007 | A Locally Advanced Breast Cancer with Difficult Differential Diagnosis of Carcinosarcoma and Atypical Medullary Carcinoma, which had Poor Response to Adriamycin- and ...
| CANCER RESEARCH AND TREATMENT |
| 2012 | A new prognostic index model using meta-analysis in early-stage epithelial ovarian cancer. | GYNECOLOGIC ONCOLOGY |
| 2016 | A novel TP53-KPNA3 translocation defines a de novo treatment-resistant clone in osteosarcoma
| COLD SPRING HARBOR MOLECULAR CASE STUDIES |
| 2017 | A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors | INVESTIGATIONAL NEW DRUGS |
| 2010 | A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer | INVESTIGATIONAL NEW DRUGS |
| 2012 | A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy. | INVESTIGATIONAL NEW DRUGS |
| 2018 | A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer
| BMC CANCER |
| 2019 | A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer | GASTRIC CANCER |
| 2012 | A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. | INVESTIGATIONAL NEW DRUGS |
| 2016 | A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer | MOLECULAR CANCER THERAPEUTICS |
| 2009 | A phase II feasibility study of weekly paclitaxel in heavily pretreated advanced gastric cancer patients with poor performance status | ONCOLOGY |
| 2010 | A phase II study of a combined biweekly irinotecan and monthly cisplatin treatment for metastatic or recurrent gastric cancer. | AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS |
| 2002 | A phase II study of gemcitiabine monotherapy in breast cancer patients refractory to anthracycline and taxane
| CANCER RESEARCH AND TREATMENT |
| 2006 | A Phase II Study of Infusional 5-Fluorouracil and Low-Dose Leucovorin with Docetaxel for Advanced Gastric Cancer | ONCOLOGY |
| 2008 | A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer. | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2007 | A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status
| BRITISH JOURNAL OF CANCER |
| 2006 | A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens
| BRITISH JOURNAL OF CANCER |
| 2007 | A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2014 | A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer.
| BRITISH JOURNAL OF CANCER |
| 2012 | A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer | INVESTIGATIONAL NEW DRUGS |
| 2014 | A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma. | CLINICAL GENITOURINARY CANCER |
| 2018 | A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy | AAPS JOURNAL |
| 2011 | A prognostic model to predict clinical outcome in gastric cancer patients with bone metastasis | ONCOLOGY |
| 2011 | A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy
| CANCER |
| 2017 | A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma | ANNALS OF ONCOLOGY |
| 2012 | A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. | EUROPEAN JOURNAL OF CANCER |
| 2016 | A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology
| CANCER RESEARCH AND TREATMENT |
| 2022 | A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer
| NATURE COMMUNICATIONS |
| 2009 | A weighted sample size for microarray datasets that considers the variability of variance and multiplicity. | JOURNAL OF BIOSCIENCE AND BIOENGINEERING |
| 2017 | ABCB1 2677G>T/A variant enhances chemosensitivity to anti-cancer agents acting on microtubule dynamics through LAMP1 inhibition | BIOCHEMICAL PHARMACOLOGY |
| 2006 | Activation of Hypoxia-Inducible Factor-1α Is Necessary for Lysophosphatidic Acid–Induced Vascular Endothelial Growth Factor Expression
| CLINICAL CANCER RESEARCH |
| 2016 | ADAR-Mediated RNA Editing Predicts Progression and Prognosis of Gastric Cancer | GASTROENTEROLOGY |
| 2010 | Adenocarcinoma of the small bowel at a single Korean institute: management and prognosticators | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY |
| 2001 | Adjuvant 5-fluorouracil plus doxorubicin in D2-3 resected gastric carcinoma: 15-year experience at a single institute. | CANCER |
| 2011 | Advanced detection of recent changing trends in gastric cancer survival: up-to-date comparison by period analysis.
| JAPANESE JOURNAL OF CLINICAL ONCOLOGY |
| 1998 | Alpha-fetoprotein-producing gastric cancer | ONCOLOGY REPORTS |
| 2006 | Alteration of hTERT full-length variant expression level showed different gene expression profiles and genomic copy number changes in breast cancer | ONCOLOGY REPORTS |
| 2007 | An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients
| ONCOLOGIST |
| 2007 | An Attempt for Combining Microarray Data Sets by Adjusting Gene Expressions
| CANCER RESEARCH AND TREATMENT |
| 2012 | An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. | EUROPEAN JOURNAL OF CANCER |
| 1998 | An unusual case of gastric carcinoma with synchronous non-Hodgkin's lymphoma
| YONSEI MEDICAL JOURNAL |
| 2022 | Analytical and Clinical Validation of Cell-Free Circulating Tumor DNA Assay for the Estimation of Tumor Mutational Burden | CLINICAL CHEMISTRY |
| 2014 | Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review
| INTERNATIONAL JOURNAL OF ONCOLOGY |
| 2014 | Angiogenic factor thymidine phosphorylase associates with angiogenesis and lymphangiogenesis in the intestinal-type gastric cancer | PATHOLOGY |
| 2008 | Angiogenic factor thymidine phosphorylase increases cancer cell invasion activity in patients with gastric adenocarcinoma.
| MOLECULAR CANCER RESEARCH |
| 2014 | Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients.
| BRITISH JOURNAL OF CANCER |
| 2021 | Antibody-Based Targeting of Interferon-Beta-1a Mutein in HER2-Positive Cancer Enhances Antitumor Effects Through Immune Responses and Direct Cell Killing
| FRONTIERS IN PHARMACOLOGY |
| 2013 | Application of the Adjuvant! Online Model to Korean Breast Cancer Patients: An Assessment of Prognostic Accuracy and Development of an Alternative Prognostic Tool | ANNALS OF SURGICAL ONCOLOGY |
| 2012 | Application of the Western-based adjuvant online model to Korean colon cancer patients; a single institution experience.
| BMC CANCER |
| 2022 | Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial
| EUROPEAN UROLOGY |
| 2016 | Assessment of Adrenal Function and Health-Related Quality of Life in Advanced Gastric Cancer Patients Who Received First-Line Chemotherapy. | ONCOLOGY |
| 2010 | Association of the ABCB1 3435C>T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy. | ONCOLOGY REPORTS |
| 2009 | Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients
| ANNALS OF ONCOLOGY |
